Controlled release formulation
Patent 4756911 Issued on July 12, 1988. Estimated Expiration Date: 
April 16, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 16, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2887440 3065143 3427378 3444290 3458622 3555151 3574820 Solid therapeutic preparation remaining in stomach Sustained release tablet formulations Sustained release indomethacin InventorsAssigneeApplicationNo. 06/852681 filed on 04/16/1986US Classes:424/468, Sustained or differential release type424/469, Discrete particles in supporting matrix424/470, Where particles are granulated424/471, Plural concentric cores424/472, Layered unitary dosage forms424/474, Coated pills or tablets424/475, Organic coatings424/480, Cellulose or derivative424/488Polysaccharides (e.g., cellulose, etc.)ExaminersPrimary: Rose, Shep K.Attorney, Agent or FirmInternational ClassesA61K 9/20 (20060101)A61K 9/28 (20060101) AbstractA controlled release pharmaceutical formulation which undergoes substantially or approaches zero order release of active drug is provided, preferably in the form of a coated tablet, containing a core portion from which medicament, such as procainamide hydrochloride, is slowly released over a controlled length of time. The core also includes one or more primary hydrocolloid gelling agents which is a hydropropylmethyl cellulose having a viscosity of within the range of from about 1,000 to about 6,000 centipoises in 2% solution at 20° C., and a methoxyl content of 28-30%, optionally a secondary hydrocarbon gelling agent, such as hydroxypropyl cellulose and/or methyl cellulose, one or more non-swellable binders and/or wax binders (where the medicament and/or hydrocolloid gelling agents are non-compressible), one or more inert fillers or excipients, one or more lubricants, and optionally one or more anti-adherents such as silicon dioxide and water. The above-described core is coated with a pharmaceutical coating composition containing a hydrophobic polymer and a hydrophilic polymer.Field of SearchCellulose or derivativeContaining solid synthetic polymers Polysaccharides (e.g., cellulose, etc.) Sustained or differential release type Discrete particles in supporting matrix Where particles are granulated Plural concentric cores Layered unitary dosage forms Coated pills or tablets Organic coatings | |
